| Literature DB >> 35815277 |
Linjia Peng1, Ke Zhang1, Yujie Li1, Lianyu Chen1, Huifeng Gao1, Hao Chen1.
Abstract
While randomized controlled trials (RCTs) are the gold standard for evidence-based medicine, they do not always reflect the real condition of patients in the real-world setting, which limits their generalizability and external validity. Real-world evidence (RWE), generated during routine clinical practice, is increasingly important in determining external effectiveness of the tightly controlled conditions of RCTs and is well recognized as a valuable complement to RCTs by regulatory bodies currently. Since it could provide new ideas and methods for clinical efficacy and safety evaluation of traditional Chinese medicine (TCM) and high-quality evidence support, real-world study (RWS) has received great attention in the field of medicine, especially in the field of TCM. RWS has shown desirable adaptability in the clinical diagnosis and treatment practice of traditional Chinese medicine. Consequently, it is increasingly essential for physicians and researchers to understand how RWE can be used alongside clinical trial data on TCM. Here, we discuss what real-world study is and outline the benefits and limitations of real-world study. Furthermore, using examples from TCM treatment on cancer, including Chinese herbal medicine, acupuncture, moxibustion, integrated TCM and Western medicine treatment, and other treatments, we elaborate how RWE can be used to help inform treatment decisions when doctoring patients with cancer in the clinic.Entities:
Year: 2022 PMID: 35815277 PMCID: PMC9259235 DOI: 10.1155/2022/7770380
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.650
The distinction between real-world study and randomized controlled trials, cohort studies, and case reports.
| Characteristic | Randomized controlled trials (RCT) | Real-world study (RCT) | Cohort study | Case-control study |
|---|---|---|---|---|
| Purpose | Focused on efficacy | Diverse research purposes, including efficacy studies | Test etiological hypotheses, evaluate preventive effects, and study the natural history of disease | Explore the cause of disease |
|
| ||||
| Study population | Ideal world crowd and strict standards of inclusion and exclusion | Real-world population and broader inclusion and exclusion criteria | Exposure to study factors and control groups | People with and without the disease |
|
| ||||
| Sample size | Calculated according to statistical formula, the sample size is limited | Calculated based on the real world or statistical formula, the sample size can be large or small | Calculated according to statistical formula, the sample size is required to be large | Calculated based on the study design or statistical formula, the sample size is small |
|
| ||||
| Research time | Shorter (mostly end with the assessment of outcome) | Short term or long term (to obtain all treatments and long-term clinical outcomes as endpoints) | Longer research time, long follow-up time | Shorter (depends on the purpose) |
|
| ||||
| Outcome | Internal validity | High external validity | Internal authenticity is not as good as RCT, and external authenticity is not as good as RWS | Both internal and external authenticity are deficient |
|
| ||||
| Design | Randomization, control, prospective study | Random or nonrandom sampling, prospective or retrospective study | Prospective or retrospective or ambispective cohort study | Control, contrast |
|
| ||||
| Implementation scenario | Highly standardized environment | Medical institutions, communities, homes, etc. | Medical institutions and communities | Medical institutions and communities |
|
| ||||
| Data | Standardization, strict specification of the collection process | Diverse sources and high heterogeneity | Different confounding factors and bias | Different confounding factors and bias, heterogeneity |
Acupuncture and other treatments in the treatment of tumor-related complications and adverse reactions.
| Disease or symptom | Acupuncture and other treatments | Primary outcome | Therapeutic effect |
|---|---|---|---|
| Cancer-related pain (CRP) [ | Acupoints on the back (back-shu points) | Pain level measured with numerical rating scale (NRS) | Relieve cancer-related pain at midtreatment and posttreatment |
|
| |||
| Breast cancer-related symptom [ | Acupuncture | Improvement and relief of symptoms | Perceived improvement in muscle pain, postsurgical pain, hot flushes, nausea/vomiting, low mood/depression, anxiety, lymphedema, and neuropathy |
|
| |||
| Breast cancer-related flushes and night sweats [ | Auricular acupuncture | Improvement of hot flushes and night sweats (HFNS) associated with adjuvant hormonal treatments | Relief from hot flushes and night sweats |
|
| |||
| Cancer pain [ | Acupuncture | Pain level measured with numerical rating scale (NRS) and daily opioid dose | Pain improved and opioid use decreased |
|
| |||
| Cancer-related insomnia [ | Electroacupuncture | Insomnia Severity Index (ISI), Pittsburgh Sleep Quality Index(PSQI), sleep diary and actigraphy-derived sleep parameters, functional assessment of cancer therapy-fatigue (FACT-F), Montreal Cognitive Assessment (MoCA), and salivary levels of cortisol and melatonin | Improvements in various sleep indicators |
The integrated TCM and Western medicine treatment in the real-world clinical practice.
| Cancer | Treatment | Primary outcome | Therapeutic effect |
|---|---|---|---|
| Hepatocellular carcinoma [ | Jianpi Liqi Fang and transcatheter arterial chemoembolization | Karnofsky performance status and traditional Chinese medicine (TCM) syndrome scores | Serum aspartate aminotransferase levels and total bilirubin levels decreased; Fibulin-5 displayed the largest difference |
|
| |||
| Postoperative colorectal cancer [ | Bushen-Jianpi-Jiedu decoction combined with chemotherapeutic drugs (oxaliplatin) | Progression-free survival (PFS) and Karnofsky performance score (KPS) | Prolongs the survival and improves Karnofsky performance status |
|
| |||
| Nonsmall cell lung cancer [ | Kangliu Jiandu formula combined with chemotherapy | Improvement rate of traditional Chinese medicine syndrome, curative effect of TCM syndrome, Karnofsky performance status (KPS) score, European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire-Lung Cancer | Significantly decreased the symptom area of QLQ-C30 and QLQ-LC13 score and increased the overall health status score of QLQ-C30, which were better than the control group |
|
| |||
| Breast cancer [ | Chinese herbal medicine combined with Western medicine | Quality of life, frequency of symptom distress, and clinical safety | Higher red blood cell counts and lower liver function |
|
| |||
| Castration-resistant prostate cancer [ | Fuyang Huayu prescription combined with chemotherapy (intravenous injection of docetaxel plus oral prednisone) | Level of serum prostate-specific antigen (PSA), Karnofsky physical condition scores, function assessment of cancer therapy-prostate (FACT-P) scores, and TCM symptom scores | Karnofsky, FACT-P, and TCM symptom scores were all markedly improved |
The results of TCM treatment of common tumors (types of cancer, title of literature, Chinese herbal medicine, primary outcome, and improvements in other areas).
| Type of cancer | Title of literature | Chinese herbal medicine | Primary outcome | Improvements in other areas |
|---|---|---|---|---|
| Advanced lung adenocarcinoma | Adjunctive traditional Chinese medicine improves survival in patients with advanced lung adenocarcinoma treated with first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a nationwide, population-based cohort study [ |
| Overall survival and progression-free survival | Increase efficacy and reduce toxicity |
|
| ||||
| Lung cancer | Characteristics of Chinese herbal medicine usage and its effect on survival of lung cancer patients in Taiwan [ | Bu Zhong Yi Qi Tang, Xiang Sha Liu Jun Zi Tang, and Bai He Gu Jin Tang; and Bei Mu, Xing Ren, and Ge Gen | The mortality hazard ratio | — |
|
| ||||
| Lung cancer | Traditional Chinese medicine as adjunctive therapy improves the long-term survival of lung cancer patients [ | Qing Zao Jiu Fei Tang, Jia Wei Xiao Yao San, Xuefu Zhuyu decoction | All-cause death | Reduction of nausea and vomiting, host immune response stimulation |
|
| ||||
| Pancreatic cancer | Complementary Chinese herbal medicine therapy improves survival of patients with pancreatic cancer in Taiwan: a nationwide population-based cohort study [ | Bai Hua She She Cao and Xiang Sha Liu Jun Zi Tang | The hazard ratio of mortality risk | Reduce gastrointestinal symptoms, anxiety, and insomnia |
|
| ||||
| Liver cancer | Adjunctive traditional Chinese medicine therapy improves survival of liver cancer patients [ | Jia Wei Xiao Yao San and Chai Hu Shu Gan Tang | All-cause mortality during the 11-year follow-up | Reduce nausea, vomiting, lipoproteinemia, chronic gastritis, and appetite loss |
|
| ||||
| Middle and advanced colorectal cancer | Clinical observation on the combination of spleen detoxification and Tongluo formula with tegafur in the maintenance treatment of middle and advanced colorectal cancer in the real world [ | Spleen detoxification and Tongluo formula | The KPS, DFS, OS, and toxic side effects | Reduce intestinal obstruction, cancer ascites, and other complications and toxic side effects of radiotherapy and chemotherapy |
|
| ||||
| Gastric cancer | Complementary Chinese herbal medicine therapy improves survival of patients with gastric cancer in Taiwan: a nationwide retrospective matched-cohort study [ | Bai Hua She She Cao and Xiang Sha Liu Jun Zi Tang | The HR of mortality risk and survival probability | Relieve cancer-related fatigue or gastrointestinal disorders |
|
| ||||
| Metastatic gastric cancer | Effect of Fuzheng Qingdu therapy for metastatic gastric cancer is associated with improved survival: a multicenter propensity-matched study [ | Shenmai and Compound Kushen injections, Shenqi Shiyi Wei Granule | Overall survival and progression-free survival | Enhance clinical efficacy and reduce adverse effects |
|
| ||||
| Breast cancer | Danshen improves survival of patients with breast cancer, and dihydroisotanshinone I induces ferroptosis and apoptosis of breast cancer cells [ | Danshen | Survival probability | Diminish the systemic cancer treatment-related adverse effects |
|
| ||||
| Breast cancer | Influence of traditional Chinese medicine on medical adherence and outcome in estrogen receptor (+) breast cancer patients in Taiwan: a real-world population-based cohort study [ | — | Evaluation of medication adherence to HT | Prevent recurrence and metastasis, delay tumor progression, and prolong survival |
|
| ||||
| Breast cancer, endometrial cancer | The use of Chinese herbal medicine products and its influence on tamoxifen-induced endometrial cancer risk among female breast cancer patients: a population-based study [ | Jia Wei Xiao Yao San and Shu Jing Huo Xue Tang | The HR for the development of endometrial cancer among CHP users | — |
|
| ||||
| Cervical cancer | Adjunctive Chinese herbal medicine treatment is associated with an improved survival rate in patients with cervical cancer in Taiwan: a matched cohort study [ | Bai Hua She She Cao and Jia Wei Xiao Yao San | Survival probability | Improve the side effects of chemo- or radiotherapy such as dysfunction of liver, diarrhea, fatigue, and pain |
|
| ||||
| Head and neck cancer | The use of adjunctive traditional Chinese medicine therapy and survival outcome in patients with head and neck cancer: a nationwide population-based cohort study [ | Gan Lou Yin | All-cause mortality during the 11-year follow-up | Attenuate toxicity and enhance the efficacy of allopathy, improving phagocytosis |
|
| ||||
| Esophageal cancer | The real-world study of the clinical efficacy of traditional Chinese medicine in the treatment of III-IV stage esophageal cancer [ | Dan Shen, Huang Qi, Fu Ling, San Qi, Wei Ling Xian, and Sheng Di | Over survival | Improve the curative effect and quality of life and reduce the adverse reaction of digestive tract and blood toxicity |
The types of syndrome differentiation of common tumors.
| Cancer | Syndrome differentiation |
|---|---|
| Lung cancer [ | Lung stagnation phlegm stasis syndrome, spleen deficiency phlegm dampness syndrome, yin deficiency phlegm heat syndrome, and qi-yin deficiency syndrome |
|
| |
| Pancreatic cancer [ | Blood stasis syndrome, spleen blood stasis syndrome, stomach qi up syndrome, and spleen yin deficiency syndrome |
|
| |
| Liver cancer [ | Qi stagnation and blood stasis syndrome, damp-heat accumulation syndrome, liver depression and spleen deficiency syndrome, and liver and kidney yin deficiency syndrome |
|
| |
| Colorectal cancer [ | Accumulated damp-heat syndrome, deficiency of both qi and blood syndrome, deficiency of liver and kidney yin syndrome, deficiency of spleen and kidney yang syndrome, and qi stagnation due to spleen deficiency syndrome |
|
| |
| Gastric cancer [ | Liver and stomach disharmony syndrome, qi stagnation and blood stasis syndrome, yin deficiency and internal heat syndrome, spleen and kidney yang deficiency syndrome, and qi and blood deficiency syndrome |
|
| |
| Breast cancer [ | Phlegm and blood stasis mutual syndrome, liver stagnation and qi stagnation syndrome, and Chong-Ren imbalance syndrome |
|
| |
| Cervical cancer [ | Deficiency of spleen and kidney yang syndrome, deficiency of liver and kidney yin syndrome, stagnation of liver and qi syndrome, and accumulation of heat toxin syndrome |
|
| |
| Esophageal cancer [ | Spittoon and qi blocking syndrome, phlegm and blood stasis syndrome, and qi deficiency and yang microsyndrome |
Figure 1The antitumor mechanism of traditional Chinese medicine.